(1)Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, U.S.A.
(2)Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan It has been shown that chronic graft-versus-host disease (cGVHD) incidence is significantly increased in male recipients receiving allogeneic hematopoietic cell transplant from female donors (F M HCT). 1,2 B-cell immunity plays a critical role in cGVHD development, 3, 4 and we have so far investigated clinically relevant immune responses against minor antigens encoded by the Y-chromosome (HY-antigens) following F M HCT. [5] [6] [7] Recently,
we have demonstrated that in F M HCT, antibody responses against HY-antigens (HY-Ab) are correlated with cGVHD and that the cumulative number of HY-Abs three months post-HCT could significantly predict cGVHD development and non-relapse mortality.
used for 57% (Table S1 ). The Stanford data confirmed female donor HY-Ab prevalence and assessed association between presence of HY-Ab in female donors and post-HCT HY-Ab development in male recipients. This study was approved by the institutional review board of Stanford University and NMDP. All patients gave written informed consents for the cryopreservation and analyses of blood samples in accordance with the Declaration of Helsinki.
In the 289 NMDP female unrelated donor cohort, half of female donors (49%) were found to have at least one of the five HY-Abs ( Figure 1A ) and antibody was detected most frequently against UTY and DBY which are the immune dominant HY-antigens following F M HCT. 5, 8 Of the 289 patients, 75 patients (26%) had one HY-Ab, 39 patients (13%) had two HY-Abs, and 29 patients (10%) had three or more HY-Abs. A similar distribution of HY-Abs was observed in the 90 Stanford female donor cohort (mainly from related sisters, Figure 1A ) and the prevalence of individual HY-Abs did not significantly differ from the NMDP cohort.
Next, we assessed the association of donor HY-Abs with donor parity and donor age (range: 18-60) in the NMDP cohort. Given that women who give birth to multiple boys are reported to have anti-HY-immunity, 10, 11 we expected multiparous female donors would have higher levels of HY-seropositivity. However, detection of any HY-Abs in female donors was not associated with donor parity (Table S2) . One possible explanation for the absence of association is that the information on the gender of births had not been collected. Further information on birth gender might reveal a positive association, although privacy concerns should be considered. Alternatively, HY-immunity may result from other male interactions besides childbirth. 12,13 While there was also no difference in age between female donors testing seropositive and seronegative for any HY-Abs, the donors who had three or more HY-Abs detected (high HY-score) were significantly older (P=0.02, Table S2 ). We believe the increased HY-score in older female donors may have resulted from cumulative male exposures and not isolated birth events. Analysis of the data from the Stanford cohort similarly showed no association between donor age and individual HY-Ab seropositivity in female donors. Parity information was not available in the Stanford cohort.
As our primary research endpoint, cGVHD incidence was assessed in F M HCT recipients in the NMDP cohort. Overall cGVHD incidence was 46% (95%CI: 40-52%).
Analysis was first carried out for individual HY-Ab detections in female donors prior to transplant. There was no statistical difference in cGVHD incidence in male recipients according to the detection of individual HY-Abs in female donors ( Figure 2A ). Analysis was then expanded to include detection of multiple HY-Abs (as reported by the HY-score) in female donors, and no significant association with cGVHD incidence in male recipients was observed in either univariate or multivariate analyses ( Figure 2B and Table S3 ). Furthermore, we did not find any association between donor HY-score and other recipient clinical outcomes ( Figure S1 and Table S3 ). This absence of association between HY-score in female donors and cGVHD development in corresponding male recipients was similarly observed in the analysis of the Stanford cohort and when the two cohorts were combined for analysis. (Table 1) . Rather, individual HY-Abs post-HCT seem to develop frequently from donors who were seronegative for the specific HY-antigen, and the positive predictive value for HY-Ab development three months post-HCT was 25% in DBY-IgG, 38% in UTY-IgG, and 0% in the other three antigens (Table 1) . Thus these results provide little evidence that adoptive humoral HY-immunity transfers from female donors to male recipients. Consistent with our HY-Ab findings, a prior CIBMTR analysis showed that the greatest increase in cGVHD risk in F M HCT was due to sex-mismatch disparity itself rather than donor parity (41% for multiparous female donors vs. 39% for nulliparous female donors vs.
30% for male donors). 2 This lack of difference in cGVHD incidence between those with nulliparous and parous female donors can be supported by the absence of HY-immunity transfer from female donors to male recipients in our current study. Together, this clinical study The absence of adoptive humoral HY-immune transfer might raise a concern for the efficacy of donor vaccination strategies to augment humoral graft-versus-leukemia benefit.
Similar to HY-immunity, pre-sensitized donor anti-tumor humoral immunity may not be effectively transferred to recipients. Human clinical trials in multiple myeloma have included donor immunization followed by recipient booster vaccination. In the recent trial, an increase of anti-idiotype IgG was limited to only 3 of 10 recipients after post-HCT boost vaccination, even though it could be induced and detected in most similarly vaccinated donors. 14 Post-HCT vaccination /sensitization may be critical for the development of effective allo-/anti-tumor humoral immunity.
Our study may have some limitations. First, the current study was retrospective, but two different cohorts independently produced similar results, providing strong evidence for the absence of an association of donor HY-seropositivity with clinical outcomes. Second, this study sample size might still be too small to detect a significant impact of donor HY-seropositivity. If a larger sample size is needed than the almost 300 patients in this study to detect an association, the impact for female donor HY-seropositivity is unlikely to be clinically significant or influential project, analyzed data, wrote / revised the manuscript, and was responsible for the study.
Conflict of interest
The authors report no conflicts of interest regarding this study. 
HCT, allogeneic hematopoietic cell transplantation; Pt, patient
We selected the time point of three months as a representative for an early time point because our previous study 8 
Proteomic microarrays for the detection of HY antibodies
In this study, a panel of five H-Y antigens was tested on our proteomic micrroarray: and then assessed separately. Mean fluorescence intensity (MFI) of each spot was obtained.
The threshold of each HY-Ab seropositivity was determined from 60 healthy male donors, and the positive cutoff was defined as the third quartile + 2 times the interquartile range (Q3+2*IQR). Relative HY-Ab quantification was shown as a factor of each H-Y seropositive threshold.
Definitions of categories
Early disease risk was defined as following: the 1st complete remission (CR) for acute leukemia; the 1st chronic phase for chronic myeloid leukemia ( HLA-matched unrelated donor (MUD), and HLA-mismatched unrelated donor (MMUD). Cord blood transplant was not included in this study. The diagnosis and severity of acute GVHD (aGVHD) for both cohorts were reported based on traditional grading scores. 13 The diagnosis of chronic GVHD (cGVHD) was reported based on the classical criteria 14 and NIH classification 15 for the NMDP cohort and the Stanford cohort, respectively. To address impact of detection of multiple HY-Abs, HY-score was defined as the sum total of HY-Ab seropositivity.
Regarding UTY, samples reactive with any one of UTY 1-3 were scored as positive for UTY.
HY-score indicates recognition of 0 to 5 HY-Abs.
Statistical analysis
Chi-Square or Mann-Whitney tests were used to compare discrete or continuous factors between the H-Y seropositive and seronegative female donors. Primary clinical endpoint was cGVHD incidence according to donor H-Y seropositivity. The cumulative incidences of clinical outcomes (acute and chronic GVHD, relapse, non-relapse mortality (NRM)) were estimated by Gray's method considering death without event as a competing risk. Overall survival (OS) from HCT was estimated by the Kaplan-Meier Method and compared by log-rank test. These probabilities were estimated with a 95% confidence interval (CI). In a multivariate analysis, we examined the association of between HY-score and various outcomes of interest adjusting for potential confounders. To this end, the Cox regression was used and the primary independent variable, "HY-score in donor", was held in all models regardless of its significance level. To adjust for confounding effect, we have considered the following prognostic factors: age of patients and donors, disease, disease status, performance status, graft type, CMV serostatus, number of donor pregnancies, conditioning regimen, and GVHD prophylaxis. For each outcome of interest (e.g., time to relapse or time to cGVHD), the stepwise model selection procedures were applied to select confounding factors along with HY-score in donor to build a prognostic model with a threshold P-value of 0.05 for variable selections. Due to the stepwise variable selection, the nominal p-value and confidence intervals of the coefficients for the selected variables may not be reliable and further validation with independent data is needed. In all the final models, the proportional hazard assumption for all prognostic variables under consideration was examined by testing their interaction with a transformation of time. In all the analyses, P-value < 0.05 was considered to be significant except for the analysis of individual HY-Abs, where P<0.01 was applied for the purpose of addressing the potential concern of multiple comparisons. SAS software version 9.2 (SAS Institute, Cary, NC) was used for the analysis of the NMDP cohort, and Stata ver.12.0 (StataCorp, College Station, TX, USA) and EZR 
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